Trial Profile
Lenalidomide and azacitidine for patients with lower risk myelodysplastic syndrome
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 25 Oct 2016
Price :
$35
*
At a glance
- Drugs Azacitidine (Primary) ; Lenalidomide (Primary)
- Indications Myelodysplastic syndromes
- Focus Therapeutic Use
- 25 Oct 2016 New trial record